Companies / PNV

POLYNOVO LIMITED

ASX:PNVHealth Care Equipment & Services
690.8M shares on issueASX (delayed) · as of 28 July 2026$0.81price · delayed$590.7Mmarket cap · indicative
A
Dilution grade

No major dilution pressure signals in current disclosures

Cash runwayno data — not a quarterly (4C/5B) cash filer
Share-count growth (24m)0.0%
Raise cadence (24m)0 cash raises
Options & rights overhang1.6% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

POLYNOVO LIMITED's ordinary share count stood at 691M as of November 2024, unchanged (0.0%) since August 2024. There were no capital raises in the 24‑month window. Options and rights on issue could convert into 11M new shares, equal to 1.6% of the current share count, of which 0% are in the money. The company does not have a current quarterly cash report on record, so no quarterly cash balance or funding-runway figure is disclosed. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
1.6%
Max option dilution
0.0%
ITM option dilution
0
Raises · last 12 months
—
Cash cover · not a quarterly filer

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 690.8M per ASX (delayed) (28 July 2026).
688.1M690.8M693.6MDec 24Sept 25July 26

Cash runway

Not a quarterly cash filer. This company does not lodge Appendix 4C/5B quarterly cash reports, so cash runway does not apply.

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
28 Nov 20243G · unquotedORDINARY FULLY PAID690.8MAppendix 3G
28 Nov 20242A · quoted issuePNV : ORDINARY FULLY PAID690.8MAppendix 2A
28 Nov 20243H · cancellationPNV : ORDINARY FULLY PAID690.8MAppendix 3H
4 Oct 20242A · quoted issuePNV : ORDINARY FULLY PAID690.8MAppendix 2A
23 Aug 20243G · unquotedORDINARY FULLY PAID690.2MAppendix 3G
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

No equity raises in the last 24 months.
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

1.6%
Total overhang · of current shares
0.0%
In the money · at current price
11.1M
Potential new shares
—
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
12 Mar 2026Mr Robert DouglasBuy151k—$100k3Y notice
25 Feb 2026Leon HoareBuy30k—$28k3Y notice
24 Feb 2026Mr Andrew LumsdenBuy100k—$91k3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

27 July 2026Becoming a substantial holder
23 July 2026Ceasing to be a substantial holder
22 July 2026$PPolyNovo FY26 Trading Update
29 June 2026Change in substantial holding
24 June 2026Becoming a substantial holder
23 June 2026Ceasing to be a substantial holder
22 June 2026Change in substantial holding
5 June 2026Ceasing to be a substantial holder
3 June 2026Change in substantial holding
29 May 2026U.S. Pivotal Trial CSR Finalised and PMA Submission Update
24 May 2026Change in substantial holding
20 May 2026Ceasing to be a substantial holder
19 May 2026Becoming a substantial holder
14 May 2026$PResponse to ASX Price Query
7 May 2026Change in substantial holding
30 Apr 2026Updated Share Trading Policy
21 Apr 2026Appointment of Dr Marthe DOmbrain as Chief Scientific Offic
31 Mar 2026Initial Director's Interest Notice - Charmaine Gittleson
24 Mar 2026Director Appointment - Charmaine Gittleson
16 Mar 2026Change of Director's Interest Notice - Robert Douglas

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.